

# *Scientific CV of Andrea Di Santo*

## ***Personal data***

Name and surname: Andrea Di Santo

Date and place of birth: 28<sup>th</sup> May 1997, Bagno a Ripoli (FI), Italy

Nationality: Italian

Institutional e-mail: [andrea.disanto@unifi.it](mailto:andrea.disanto@unifi.it)

## ***Vocational training***

In 2016 I obtained the high school diploma at I.T.A.S. Ginori Conti (Florence, Italy) in Environmental Biotechnologies with a grade of 100/100. In the same year I enrolled in University of Florence in Chemistry faculty. In 2019 I obtained the 1st level Degree in Chemistry with a grade of 110/110 *cum laude* with the thesis "Metformin analogue functionalized with fluorescent probe", supervisor Prof. Stefano Cicchi. In 2022 I obtained the 2nd level Degree in Organic Chemistry, with a grade of 110/110 *cum laude* with the master thesis "Design, synthesis, and biological evaluation of peptides derived from Spike protein and nucleocapsid protein of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2)", supervisor Prof. Anna Maria Papini. After graduation I won the research fellowship "Research and development of efficient and sustainable molecules in industrial processes" founded by the Chemistry Department of the University of Florence. In November 2022 I obtained a PhD scholarship in Pharmaceutical Sciences at NEUROFARBA Department, University of Florence, with thesis titled "Preliminary characterization of drug and anti-drug antibodies in patients treated with adalimumab using Surface Plasmon Resonance (SPR)".

## ***Publications***

**2023** - SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein; Stincarelli, M. A.; Quagliata, M.; Di Santo, A.; Pacini, L.; Fernandez, F. R.; Arvia, R.; Rinaldi, S.; Papini, A. M.; Rovero, P.; Gianecchini, S. SARS-CoV-2 Inhibitory Activity of a Short Peptide Derived from Internal Fusion Peptide of S2 Subunit of Spike Glycoprotein. *Virus Research* 2023, 334, 199170.

**2023** - Therapeutic proteins immunogenicity: a peptide point of view; Real-Fernandez, F.; Errante, F.; Di Santo, A.; Papini, A. M.; Rovero, P. Therapeutic Proteins Immunogenicity: A Peptide Point of View. *Explor Drug Sci* 2023, 377–387.

## ***Scientific contributes***

**06/2022** - 4th National Congress of Italian Peptide Society Naples, Italy. **Oral contribute** "Antiviral peptides derived from Heptad Repeated Region 1 of Spike protein of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2)"

**08/2022** - 36th European and 12th International Peptide Symposium Sitges, Spain. **Poster presentation** "Design, synthesis, and biological evaluation of peptides derived from Spike protein of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2)".

**09/2023** - 28th National Meeting on Medicinal Chemistry Chieti, Italy. **Poster presentation** "Detection and quantification of drug and anti-drug antibodies in patients treated with the therapeutic monoclonal antibody Adalimumab using a Surface Plasmon Resonance biosensor".

**09/2023** - Giornata Scientifica ItPS 2023 dedicata ai Giovani Ricercatori Florence, Italy. **Oral contribute** "A novel method based on Surface Plasmon Resonance for detection and quantification of Adalimumab and anti-Adalimumab antibodies in sera of treated patients".

**10/2023** - 4th Autumn Meeting for Young Chemists in Biomedical Sciences Florence, Italy. **Oral contribute** "Surface Plasmon Resonance biosensor to detect and quantify drug and anti-drug antibodies in patients treated with the therapeutic monoclonal antibody Adalimumab".